Voyager Therapeutics and AbbVie announce global strategic collaboration to develop potential new treatments for Alzheimer’s disease and other tau-related neurodegenerative diseases. Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the…